High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy

Clinical Breast Cancer

Volumn 15, Issue 1, 2015, Pages 31-36

  Zelnak, Amelia B ^a   Nikolinakos, Petros ^b   Srinivasiah, Jayanthi ^b   Jonas, William ^b   Pippas, Andrew ^b   Liu, Yuan ^c   Li, Xiaoxian ^a   Torres, Mylin ^a   O'Regan, Ruth M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Center for Oncology Research and Education   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Breast cancer; Nab paclitaxel; Neoadjuvant chemotherapy; Pathologic complete response; Trastuzumab

Indexed keywords

AROMATASE INHIBITOR; NAVELBINE; PACLITAXEL; PEGFILGRASTIM; TAMOXIFEN; TRASTUZUMAB; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; VINBLASTINE;

ABNORMAL LABORATORY RESULT; ADJUVANT CHEMOTHERAPY; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER REGRESSION; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ADULT; ALBUMINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; RECEPTOR, ERBB-2; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84920475910     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.06.004     Document Type: Article

References (28)

1. H.D. Bear, S. Anderson, and R.E. Smith Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 2006 2019 2027
2. M. Kaufmann, G.N. Hortobagyi, and A. Goldhirsch Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 2006 1940 1949
3. P. Rastogi, S.J. Anderson, and H.D. Bear Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 2008 778 785
4. D.J. Slamon Proto-oncogenes and human cancers N Engl J Med 317 1987 955 957
5. L.A. Carey, E.C. Dees, and L. Sawyer The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2007 2329 2334
6. A.S. Caudle, T.K. Yu, and S.L. Tucker Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy Breast Cancer Res 14 2012 R83
7. L.J. Esserman, D.A. Berry, and M.C. Cheang Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Breast Cancer Res Treat 132 2012 1049 1062
8. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
9. A.U. Buzdar, N.K. Ibrahim, and D. Francis Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 2005 3676 3685
10. L. Gianni, W. Eiermann, and V. Semiglazov Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 2010 377 384
11. D. Slamon, W. Eiermann, and N. Robert Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
12. J. Baselga, J. Cortes, and S.B. Kim Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
13. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
14. M.D. Pegram, G.E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D.J. Slamon Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J Natl Cancer Inst 96 2004 739 749
15. M. Andersson, E. Lidbrink, and K. Bjerre Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study J Clin Oncol 29 2011 264 271
16. B.P. Coudert, R. Largillier, and L. Arnould Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial J Clin Oncol 25 2007 2678 2684
17. S. Bayraktar, A.M. Gonzalez-Angulo, and X. Lei Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer Cancer 118 2012 2385 2393
18. L. Gianni, T. Pienkowski, and Y.H. Im Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 2012 25 32
19. A. Schneeweiss, S. Chia, and T. Hickish Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Ann Oncol 24 2013 2278 2284
20. V. Guarneri, A. Frassoldati, and A. Bottini Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study J Clin Oncol 30 2012 1989 1995
21. J. Baselga, I. Bradbury, and H. Eidtmann Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 2012 633 640
22. R. Nahta, and R.M. O'Regan Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers Breast Cancer Res Treat 135 2012 39 48
23. C.C. Benz, G.K. Scott, and J.C. Sarup Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu Breast Cancer Res Treat 24 1992 85 95
24. R.J. Pietras, J. Arboleda, and D.M. Reese HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells Oncogene 10 1995 2435 2446
25. R. Bhargava, D.J. Dabbs, and S. Beriwal Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer Mod Pathol 24 2011 367 374
26. F. Montemurro, V. Rossi, and M. Cossu Rocca Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients Cancer 118 2012 17 26
27. H. Kurokawa, A.E. Lenferink, and J.F. Simpson Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells Cancer Res 60 2000 5887 5894
28. E.A. Mittendorf, Y. Wu, and M. Scaltriti Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes Clin Cancer Res 15 2009 7381 7388